« Return to News | Awards & Advancement

Omthera raises $34 million in venture funding

Tuesday, March 15, 2011 01:34 PM

With a phase III study of its lead drug now under way, Omthera Pharmaceuticals has raised $33.9 million in its second round of venture cash. New Enterprise Associates led the round, with former MedImmune chief David Mott now slated to join the biotech's board. Sofinnova Partners, which had set up the Series A, also participated in the new round.

Much of the money will be used to complete trials for Epanova, an Omega-3 drug being positioned as a superior choice to Lovaza. At the beginning of the year, Bedminster, N.J.-based Omthera touted data demonstrating its therapy had greater bioavailability than Lovaza.

"There is a distinct market need for a more effective and convenient prescription-strength Omega-3 treatment option for patients suffering from very high triglycerides who need to maintain a low-fat diet," said Mott. "Data generated to date [indicate] that Epanova has solid promise in this area, with the potential to deliver improved and more predictable bioavailability than currently available ethyl ester based formulations of Omega-3s. Epanova has the potential to capture significant market share and eclipse currently available therapies to become the drug of choice."  

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.